Evidence map›Paper›PMID 42581265›Full record

ArticleAAPS PharmSciTech2026

Use of Benzene-Free Carbomer 980 in the Formulation of Metronidazole Gel 0.75% and Demonstration of Equivalence with Carbomer 940.

Om Sambhaji Shelke, Jie Feng, Zhong Liu, Yulan Chen, Yijie Zhu, Zheng Zhang

Abstract read
PubMed Publisher
In one paragraph

Article in AAPS PharmSciTech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Om Sambhaji ShelkeR&D Center, Sinomune Pharmaceutical Co., Ltd, Wuxi, Jiangsu, 214194, China. om.shelke20@gmail.com.ORCID http://orcid.org/0000-0001-8809-3018
Jie FengR&D Center, Sinomune Pharmaceutical Co., Ltd, Wuxi, Jiangsu, 214194, China.ORCID http://orcid.org/0009-0002-1709-6128
Zhong LiuR&D Center, Sinomune Pharmaceutical Co., Ltd, Wuxi, Jiangsu, 214194, China.ORCID http://orcid.org/0009-0006-4899-2004
Yulan ChenR&D Center, Sinomune Pharmaceutical Co., Ltd, Wuxi, Jiangsu, 214194, China.ORCID http://orcid.org/0009-0007-6360-6914
Yijie ZhuR&D Center, Sinomune Pharmaceutical Co., Ltd, Wuxi, Jiangsu, 214194, China.ORCID http://orcid.org/0009-0001-1040-512X
Zheng ZhangDepartment of Pharmacology, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, 410078, China.ORCID http://orcid.org/0000-0003-1942-6813

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The U.S. FDA currently recommends avoiding carbomer grades that contain benzene and recommends benzene-free alternatives (USFDA. Guidance for Industry: reformulating drug products that contain carbomers manufactured with benzene. Center for Drug Evaluation and Research (CDER), Pharmaceutical Quality/CMC. Published in December 2023. Available at: https://www.fda.gov/media/175083/download ). This means that if a finished product is authorized with a carbomer grade containing benzene, it needs to be replaced with a non-benzene carbomer grade. Such an update would also require detailed comparative studies-covering structure, performance, stability, and biological equivalence-to confirm consistent product quality and effectiveness. The current study attempted to replace Carbomer 940 (C940) with Carbomer 980 (C980) in 0.75% Metronidazole Gel. The two carbomer grades were characterized as powders using multiple spectroscopic techniques. A method for analyzing carboxylic acid content was developed and validated, using light-scattering resonance technology to improve accuracy. The formulation prepared with C940 and C980 was characterized for rheology, in vitro release and permeation, and stability, along with the reference formulation. Powder characterization shows slight differences in the absorption spectra across NMR and FTIR studies, while NIR spectra are the same. Additionally, C980 has a slightly higher molecular weight, degree of polymerization, apparent viscosity, and carboxylic acid content, but a lower water loss. The formulations prepared with C940 and C980 are rheologically equivalent to the reference formulation as assessed by flow curves, yield stress, linear viscoelasticity, and creep. The in vitro release and permeation study also demonstrates that the formulations prepared with C940 and C980 exhibit performance equivalence to the innovator formulation under the tested conditions. Hence, replacing the benzene-grade carbomer with the corresponding non-benzene-grade carbomer does not significantly affect product performance relative to the reference product.

Indexed as

Acrylic ResinsBenzeneMetronidazoleBulk DrugsChemistry, PharmaceuticalDrug LiberationDrug StabilityGelsRheologyAcrylic ResinsBenzeneBulk DrugscarbomerGelsMetronidazoleAnd GelCarbomer 940Carbomer 980Carbomer CharacterizationsMetronidazole

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.